Onoda J M, Nelson K K, Taylor J D, Honn K V
Department of Radiation Oncology, Wayne State University, Detroit, MI 48202.
Cancer Lett. 1988 May;40(1):39-47. doi: 10.1016/0304-3835(88)90260-1.
Resistance to cisplatin is a relative term and is at least partially attributable to its narrow therapeutic index. It is often not possible to successfully treat tumors exhibiting even a small inherent resistance to cisplatin by increasing the dose level of cisplatin, because such therapies may be fatally toxic to a patient. Thus, combination therapy with an agent which enhances cisplatin's antitumor effects with little or no enhancement of cisplatin's toxicities, may be of value in the treatment of human tumors which fail to respond to treatment with cisplatin alone. We recently reported that nifedipine, a dihydropyridine class calcium channel blocker, enhances the antitumor actions of cisplatin against a cisplatin-sensitive murine amelanotic melanoma. We now report that nifedipine enhances cisplatin's antitumor effects against a murine carcinoma (Lewis lung carcinoma) that is inherently resistant to cisplatin.
对顺铂的耐药性是一个相对的概念，至少部分归因于其狭窄的治疗指数。对于那些即使对顺铂表现出轻微内在耐药性的肿瘤，通常也不可能通过提高顺铂的剂量水平来成功治疗，因为这种疗法可能对患者具有致命毒性。因此，与一种能增强顺铂抗肿瘤作用而很少或不增强其毒性的药物联合治疗，可能对治疗单独使用顺铂无效的人类肿瘤有价值。我们最近报道，二氢吡啶类钙通道阻滞剂硝苯地平可增强顺铂对顺铂敏感的小鼠无黑色素黑色素瘤的抗肿瘤作用。我们现在报告，硝苯地平可增强顺铂对固有耐药的小鼠癌（刘易斯肺癌）的抗肿瘤作用。
